Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $6.0 million.

  • Revolution Medicines' Gains from Investment Securities rose 368.87% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 485.15%. This contributed to the annual value of $44.6 million for FY2024, which is 76.41% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Gains from Investment Securities is $6.0 million, which was down 68.60% from $18.9 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Gains from Investment Securities ranged from a high of $49.1 million in Q4 2024 and a low of -$3.9 million during Q1 2024.
  • Over the past 3 years, Revolution Medicines' median Gains from Investment Securities value was $1.3 million (recorded in 2024), while the average stood at $8.4 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first spiked by 6,841.60% in 2021, then tumbled by 1,465.38% in 2024.
  • Revolution Medicines' Gains from Investment Securities (Quarterly) stood at $35.5 million in 2021, then tumbled by 89.86% to $3.6 million in 2022, then skyrocketed by 365.48% to $16.8 million in 2023, then soared by 192.82% to $49.1 million in 2024, then spiked by 368.87% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $18.9 million for Q2 2025, and -$2.4 million during Q1 2025.